Juno Therapeutics, a Seattle, Washington biopharmaceutical company developing cancer immunotherapies, and Thermo Fisher Scientific have formed a partnership for Juno to use Thermo Fisher’s Cell Therapy Systems (CTS) activation reagents in the manufacturing of its chimeric antigen receptor T cell (CAR T) therapies.

Under the seven-year nonexclusive licensing and supply agreement, Juno has obtained rights to use CTS Dynabeads CD3/CD28 magnetic beads as part of the clinical and commercial manufacturing processes for its current and future CAR-T therapies. CTS Dynabeads are designed to activate and expand T cells that have been genetically engineered to recognize and fight cancer cells in each individual patient.

Source: Thermo Fisher Scientific